AzaSite (1% azithromycin ophthalmic solution) / Sun Pharma, Akorn, Nicox - LARVOL DELTA

"Huzzah! Azasite lives to see another day! My latest for #OSN https://t.co/emmSvBYpip @LizYeu @LaurenBLevine @Dryeyemaster @djmjspin @TalRavivMD @cataractMD @cataractsurgery @CathyEye @DrRobMelendez @preeyakgupta" (@DarrellWhite)

Surgery • Cataract • Dry Eye Disease • Ophthalmology

Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - P=N/A | N=20 | Completed | Sponsor: Washington University School of Medicine | Active, not recruiting ➔ Completed | Trial completion date: Dec 2022 ➔ Aug 2022 | Trial primary completion date: Dec 2022 ➔ Aug 2022

Trial completion • Trial completion date • Trial primary completion date

"Azasite is the "hot potato" again. Will Thea keep it? My latest: https://t.co/ycvUUA3XS4 @n8radcliffe gets a question! @preeyakgupta @LizYeu @djmjspin @Dryeyemaster @drfishman" (@DarrellWhite)

Dry Eye Disease • Ophthalmology

Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - P=N/A | N=20 | Active, not recruiting | Sponsor: Washington University School of Medicine | Trial completion date: Dec 2021 ➔ Dec 2022 | Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date

Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - P=N/A; N=20; Active, not recruiting; Sponsor: Washington University School of Medicine; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Clinical • Trial completion date • Trial primary completion date

Blog: More AzaSite drama (Healio) - "In everyone's defense, AzaSite is a terrifically difficult drug to market and sell now that we are no longer in the 'approve and move' world where you get a very narrow indication for a drug and then shadow market all kinds of other uses. While it is actually a brilliant drug for its on-label indication, treating bacterial conjunctivitis, 95+% of AzaSite scripts are for meibomian gland dysfunction treatment. Tough sell, even for a drug that works so well in such a common entity. Without a change in label, AzaSite is likely to languish in the wings as it has been doing for the last 6 or 7 years at least. Which is a shame because, as I’ve oft written, it works great in the dry eye disease/ocular surface disease world."

Blog

Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - P=N/A; N=20; Active, not recruiting; Sponsor: Washington University School of Medicine; Trial primary completion date: Dec 2017 ➔ Jun 2018

Trial primary completion date • Biosimilar

Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - P=N/A; N=20; Active, not recruiting; Sponsor: Washington University School of Medicine; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Dec 2019 ➔ Dec 2020

Trial completion date • Trial primary completion date

Drugs for common eye disorders. (PubMed, Med Lett Drugs Ther) - No abstract available.

Journal • Review

FAM for BOS: Targeted Therapy of Bronchiolitis Obliterans Syndrome (clinicaltrials.gov) - P2; N=42; Recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Trial primary completion date: May 2014 ➔ Nov 2014

Clinical • Trial primary completion date

FAM for BOS: Targeted Therapy of Bronchiolitis Obliterans Syndrome (clinicaltrials.gov) - P2; N=5; Completed; Sponsor: Fred Hutchinson Cancer Research Center; Active, not recruiting ➔ Completed; N=42 ➔ 5

Clinical • Enrollment change • Trial completion

FAM for BOS: Targeted Therapy of Bronchiolitis Obliterans Syndrome (clinicaltrials.gov) - P2; N=42; Active, not recruiting; Sponsor: Fred Hutchinson Cancer Research Center; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed

Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - P=N/A; N=20; Active, not recruiting; Sponsor: Washington University School of Medicine; Trial completion date: Sep 2019 ➔ Dec 2019; Trial primary completion date: Jun 2019 ➔ Dec 2019

Clinical • Trial completion date • Trial primary completion date

Healthy Patients & Effect of Antibiotics (clinicaltrials.gov) - P=N/A; N=20; Active, not recruiting; Sponsor: Washington University School of Medicine; Trial completion date: Jun 2019 ➔ Sep 2019

Clinical • Trial completion date